China is rapidly strengthening its position in global pharmaceutical innovation, with new drug discoveries improving healthcare outcomes and expanding the country’s influence in the medical sector.
According to China’s drug regulator, 19 innovative medicines have been approved this year, including 15 developed domestically. International licensing deals for Chinese innovative drugs exceeded $60 billion in the first quarter, reflecting growing global confidence in the country’s research capabilities.
The recent breakthroughs include a new stroke treatment developed by Simcere that has shown promising results in protecting brain cells and improving patient recovery. Another innovation, onradivir tablets, offers a new treatment option for Influenza A and has demonstrated strong safety and effectiveness.
China’s pharmaceutical industry has made significant progress in developing treatments for major diseases such as stroke, influenza, and cancer. During the 2021–2025 period, the country approved 230 innovative drugs, with domestically developed medicines accounting for more than 80 percent of approvals in 2025.
Supported by increased research investment, faster regulatory approval processes, and growing international partnerships, Chinese pharmaceutical companies are expanding their global presence and accelerating the development of advanced therapies. These achievements highlight China’s emergence as a major force in innovative medicine and modern healthcare solutions.
Source: People’s Daily
